Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 36

1.

Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update.

Wang SM, Han C, Lee SJ, Jun TY, Patkar AA, Masand PS, Pae CU.

Chonnam Med J. 2016 Sep;52(3):159-72. doi: 10.4068/cmj.2016.52.3.159. Epub 2016 Sep 23. Review.

2.

Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study.

Sanacora G, Johnson MR, Khan A, Atkinson SD, Riesenberg RR, Schronen JP, Burke MA, Zajecka JM, Barra L, Su HL, Posener JA, Bui KH, Quirk MC, Piser TM, Mathew SJ, Pathak S.

Neuropsychopharmacology. 2017 Mar;42(4):844-853. doi: 10.1038/npp.2016.224. Epub 2016 Sep 29.

3.

Clinical application of DEX/CRH test and multi-channel NIRS in patients with depression.

Kinoshita S, Kanazawa T, Kikuyama H, Yoneda H.

Behav Brain Funct. 2016 Aug 31;12(1):25. doi: 10.1186/s12993-016-0108-x.

4.

Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort.

Lam RW, Milev R, Rotzinger S, Andreazza AC, Blier P, Brenner C, Daskalakis ZJ, Dharsee M, Downar J, Evans KR, Farzan F, Foster JA, Frey BN, Geraci J, Giacobbe P, Feilotter HE, Hall GB, Harkness KL, Hassel S, Ismail Z, Leri F, Liotti M, MacQueen GM, McAndrews MP, Minuzzi L, Müller DJ, Parikh SV, Placenza FM, Quilty LC, Ravindran AV, Salomons TV, Soares CN, Strother SC, Turecki G, Vaccarino AL, Vila-Rodriguez F, Kennedy SH; CAN-BIND Investigator Team..

BMC Psychiatry. 2016 Apr 16;16:105. doi: 10.1186/s12888-016-0785-x.

5.

Challenging Treatment-Resistant Major Depressive Disorder: A Roadmap for Improved Therapeutics.

de Sousa RT, Zanetti MV, Brunoni AR, Machado-Vieira R.

Curr Neuropharmacol. 2015;13(5):616-35. Review.

6.

Pharmacologic approaches to treatment resistant depression: Evidences and personal experience.

Tundo A, de Filippis R, Proietti L.

World J Psychiatry. 2015 Sep 22;5(3):330-41. doi: 10.5498/wjp.v5.i3.330.

7.

Optimizing the Use of Aripiprazole Augmentation in the Treatment of Major Depressive Disorder: From Clinical Trials to Clinical Practice.

Han C, Wang SM, Lee SJ, Jun TY, Pae CU.

Chonnam Med J. 2015 Aug;51(2):66-80. doi: 10.4068/cmj.2015.51.2.66. Epub 2015 Aug 17. Review.

8.

Aripiprazole Induced Acute Transient Bilateral Myopia: A Case Report.

Karadağ H, Acar M, Özdel K.

Balkan Med J. 2015 Apr;32(2):230-2. doi: 10.5152/balkanmedj.2015.15292. Epub 2015 Apr 1.

9.

Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Efficacy Results From a Randomized, Double-Blind, Placebo-Controlled Study.

Papakostas GI, Fava M, Baer L, Swee MB, Jaeger A, Bobo WV, Shelton RC.

Am J Psychiatry. 2015 Dec;172(12):1251-8. doi: 10.1176/appi.ajp.2015.14101251. Epub 2015 Jun 18.

10.

Atypical Antipsychotic Augmentation for Treatment-Resistant Depression: A Systematic Review and Network Meta-Analysis.

Zhou X, Keitner GI, Qin B, Ravindran AV, Bauer M, Del Giovane C, Zhao J, Liu Y, Fang Y, Zhang Y, Xie P.

Int J Neuropsychopharmacol. 2015 May 25;18(11):pyv060. doi: 10.1093/ijnp/pyv060. Review.

11.
12.

A Meta-Analysis Comparing Open-Label versus Placebo-Controlled Clinical Trials for Aripiprazole Augmentation in the Treatment of Major Depressive Disorder: Lessons and Promises.

Pae CU, Seo HJ, Lee BC, Seok JH, Jeon HJ, Paik JW, Kwak KP, Ham BJ, Han C, Lee SJ.

Psychiatry Investig. 2014 Oct;11(4):371-9. doi: 10.4306/pi.2014.11.4.371. Epub 2014 Oct 20. Review.

13.

Use of atypical antipsychotics in the elderly: a clinical review.

Gareri P, Segura-García C, Manfredi VG, Bruni A, Ciambrone P, Cerminara G, De Sarro G, De Fazio P.

Clin Interv Aging. 2014 Aug 16;9:1363-73. doi: 10.2147/CIA.S63942. eCollection 2014. Review.

14.
15.

Treatment-resistant depression in primary care across Canada.

Rizvi SJ, Grima E, Tan M, Rotzinger S, Lin P, Mcintyre RS, Kennedy SH.

Can J Psychiatry. 2014 Jul;59(7):349-57.

16.

Meta-analysis on the efficacy and tolerability of the augmentation of antidepressants with atypical antipsychotics in patients with major depressive disorder.

Wen XJ, Wang LM, Liu ZL, Huang A, Liu YY, Hu JY.

Braz J Med Biol Res. 2014 Jul;47(7):605-16. Epub 2014 Jun 13. Review.

17.

A neurobiological hypothesis of treatment-resistant depression - mechanisms for selective serotonin reuptake inhibitor non-efficacy.

Coplan JD, Gopinath S, Abdallah CG, Berry BR.

Front Behav Neurosci. 2014 May 20;8:189. doi: 10.3389/fnbeh.2014.00189. eCollection 2014. Review.

18.

Efficacy of adjunctive aripiprazole in patients with major depressive disorder whose symptoms worsened with antidepressant monotherapy.

Nelson JC, Rahman Z, Laubmeier KK, Eudicone JM, McQuade RD, Berman RM, Marcus RN, Baker RA, Sheehan JJ.

CNS Spectr. 2014 Dec;19(6):528-34. doi: 10.1017/S109285291300103X. Epub 2014 Mar 18.

19.

Antidepressant response to aripiprazole augmentation associated with enhanced FDOPA utilization in striatum: a preliminary PET study.

Conway CR, Chibnall JT, Cumming P, Mintun MA, Gebara MA, Perantie DC, Price JL, Cornell ME, McConathy JE, Gangwani S, Sheline YI.

Psychiatry Res. 2014 Mar 30;221(3):231-9. doi: 10.1016/j.pscychresns.2014.01.003. Epub 2014 Jan 14.

20.

Improvement in functional outcomes with adjunctive aripiprazole versus placebo in major depressive disorder: a pooled post hoc analysis of 3 short-term studies.

Fabian TJ, Cain ZJ, Ammerman D, Eudicone JM, Tang Y, Rollin LM, Forbes RA, Berman RM, Baker RA.

Prim Care Companion CNS Disord. 2012;14(6). pii: PCC.12m01394. doi: 10.4088/PCC.12m01394. Epub 2012 Dec 20.

Supplemental Content

Support Center